Janus Henderson Group Ltd. filed a Schedule 13G with the SEC on November 16, 2026, disclosing beneficial ownership of 7,196,318 common shares of Definium Therapeutics, Inc. as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: Janus Henderson Group Ltd. reported beneficial ownership of 7,196,318 common shares of Definium Therapeutics, Inc.
  • Percent of class: The 7,196,318 shares represent 5.4% of the outstanding class of common shares, according to the filing.
  • No sole voting or dispositive power: The filing states sole voting power of 0 and sole dispositive power of 0; all 7,196,318 shares are held with shared voting and shared dispositive power.
  • Triggering event date: The date of event requiring the filing was September 30, 2026.
  • Ownership held through managed portfolios: The shares are deemed beneficially owned through Asset Managers acting on behalf of investment companies, institutional separate accounts, and retail separate accounts described as "Managed Portfolios."
  • No individual portfolio exceeds 5%: According to the filing, none of the Managed Portfolios individually owns more than five percent of the common shares of Definium Therapeutics, Inc.

Janus Henderson's Schedule 13G Position in Definium Therapeutics

Janus Henderson Group Ltd., organized in Jersey and headquartered at 201 Bishopsgate, EC2M 3AE, United Kingdom, filed a Schedule 13G disclosing a 5.4% beneficial ownership position in Definium Therapeutics, Inc. (CUSIP 24477V105). The issuer's principal executive offices are listed in the filing as One World Trade Center, Suite 8500, New York, NY 10007. The filing was signed by Kristin Mariani, Head of North America Compliance, and dated November 16, 2026.

According to the filing, Janus Henderson Group Ltd. is the ultimate parent of multiple SEC-registered investment advisers and foreign equivalents, including Janus Henderson Investors US LLC, Janus Henderson Investors UK Limited, Victory Park Capital Advisors LLC, and Richard Bernstein Advisors LLC, among others. These entities, collectively referred to as the "Asset Managers," exercise investment and/or voting discretion on behalf of their clients. As a result of that discretion, the Asset Managers "may be deemed to be the beneficial owner of 7,196,318 common shares of Definium Therapeutics, Inc." The filing further states that "the Asset Managers do not have the right to receive any dividends from, or the proceeds from the sale of, the securities held in the Managed Portfolios and disclaim any ownership associated with such rights."

The filing also notes that all dividends and sale proceeds related to these shares belong to the respective Managed Portfolios. The certification included in the filing states that the securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer."

What Was Disclosed

Janus Henderson Group Ltd. disclosed a 5.4% beneficial ownership stake of 7,196,318 common shares in Definium Therapeutics, Inc. via Schedule 13G, with all shares held under shared voting and shared dispositive power through its network of Asset Managers on behalf of Managed Portfolios.